Jul 23, 2012
By:
Amy Ritter, PhD
Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.5 billion.
|
Jul 20, 2012
By:
Amy Ritter, PhD
EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Glybera (alipogene tiparvovec, marking the first recommendation in Europe for a gene therapy medicine.
|
Jul 18, 2012
By:
Amy Ritter, PhD
Par Pharmaceuticals, a maker of generic drugs, has entered into an agreement to be acquired by the private investment firm, TPG.
|
Jul 11, 2012
By:
Amy Ritter, PhD
FDA approved a risk evaluation and mitigation strategy for extended-release and long-acting opioid medications.
|
Jul 3, 2012
By:
Amy Ritter, PhD
GlaxoSmithKline has agreed to plead guilty and pay $3 billion to resolve criminal and civil liability resulting from unlawful promotion of certain drugs, failure to report safety data, and alleged false price reporting practices.
|
Industry experts from Fujifilm Diosynth and Boehringer Ingelheim discuss methods for optimizing protein expression in bacterial and mammalian cell lines.
Jul 1, 2012
By:
Amy Ritter, PhD
Industry experts discuss methods for optimizing protein expression in bacterial and mammalian cell lines.
|
Jun 28, 2012
By:
Amy Ritter, PhD
In a 5-4 ruling, the US Supreme Court upheld the provision of the Affordable Care Act requiring all adults to purchase health insurance or pay a penalty—the so-called individual mandate.
|
Jun 27, 2012
By:
Amy Ritter, PhD
Roche announced that it will be closing its R&D site in Nutley, NJ, eliminating approximately 1000 positions.
|
Jun 13, 2012
By:
Amy Ritter, PhD
Eli Lilly announced an increase in its manufacturing network in China through an expanded collaboration with Novast Laboratories, a generic and specialty pharmaceutical company based in Nantong, China.
|
|
